Evidence map›Paper›PMID 36823223›Full record

Observational studyScientific reports2023

The effect of a brief, unplanned treatment delay on neovascular age-related macular degeneration patients: a retrospective cohort study.

Jason Adam Zehden, Arko Ghosh, Srinath Soundararajan, Tamy Harumy Moraes Tsujimoto, Huijun Jiang, Feng-Chang Lin, Tyler Blahnik, David Fleischman, Alice Yang Zhang

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jason Adam ZehdenDepartment of Ophthalmology, University of North Carolina (UNC), 2226 Nelson Hwy Suite 220, Chapel Hill, NC, 27517, USA.
Arko GhoshDepartment of Ophthalmology, University of North Carolina (UNC), 2226 Nelson Hwy Suite 220, Chapel Hill, NC, 27517, USA.
Srinath SoundararajanSchool of Medicine, University of North Carolina (UNC), Chapel Hill, NC, USA.
Tamy Harumy Moraes TsujimotoDepartment of Biostatistics, University of North Carolina (UNC), Chapel Hill, NC, USA.
Huijun JiangDepartment of Biostatistics, University of North Carolina (UNC), Chapel Hill, NC, USA.
Feng-Chang LinDepartment of Biostatistics, University of North Carolina (UNC), Chapel Hill, NC, USA.
Tyler BlahnikDepartment of Ophthalmology, University of North Carolina (UNC), 2226 Nelson Hwy Suite 220, Chapel Hill, NC, 27517, USA.
David FleischmanDepartment of Ophthalmology, University of North Carolina (UNC), 2226 Nelson Hwy Suite 220, Chapel Hill, NC, 27517, USA.
Alice Yang ZhangDepartment of Ophthalmology, University of North Carolina (UNC), 2226 Nelson Hwy Suite 220, Chapel Hill, NC, 27517, USA. alice_zhang@med.unc.edu.
University of North Carolina Health Care · USUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-compliance to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy can result in increased disease activity in neovascular age-related macular degeneration (nAMD). Our study aims to determine effects of unplanned delay in anti-VEGF injection treatment for nAMD. This retrospective observational study included patients with delays in receiving intravitreal injections for nAMD treatment from March to May 2020 by at least 21 days. Baseline demographic and clinical characteristics, visual acuity (VA), central macular thickness (CMT) measured on optical coherence tomography (OCT), and duration of delayed treatment were analyzed for 3 time points, the pre-delay visit (v1) and post-delay visits (v2 and v3). Data were compared to age-matched controls treated for nAMD in 2019 without delay. Demographic characteristics were compared using two-sample t-tests for continuous variables and Pearson's chi-square tests for categorical variables. For the two primary outcomes of interest, VA and CMT, means and standard deviations were reported for each combination of group and time. Each outcome was modeled using a linear mixed model with the group, time and group-time interaction as fixed effects. A total of 69 patients (99 eyes) in the treatment delay group and 44 patients (69 eyes) in the control group were identified. Statistically significant differences between control and delayed groups were detected for VA (difference in mean logMAR = 0.16; 95% CI 0.06, 0.27; p = 0.002) and CMT (difference in mean CMT = 29; 95% CI 12, 47; p = 0.001) at v2. No differences were detected for v1 and v3 time points for both outcomes. An unplanned delay in intravitreal injection treatment for nAMD resulted in an increase in CMT and worsening of VA compared to controls observed at v2. At v3, CMT and VA recovered to near v1 levels. This study demonstrates that a one-time, brief interruption in treatment for nAMD results in reversible, temporary worsening.

Indexed as

Macular DegenerationWet Macular DegenerationAngiogenesis InhibitorsHumansIntravitreal InjectionsRanibizumabRetrospective StudiesTime-to-TreatmentTreatment OutcomeVascular Endothelial Growth Factor AAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor A

Identifiers

PMID36823223
PMCPMC9947880
OpenAlexW4321596548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.